GSDMD (gasdermin-D) promotes pyroptosis in response to microbial infection and danger signals. It is produced by the cleavage of gasdermin-D by inflammatory caspases CASP1 or CASP4 in response to canonical, as well as, non-canonical (such as cytosolic LPS) inflammasome activators. After cleavage, GSDMD moves to the plasma membrane where it strongly binds to inner leaflet lipids including phosphatidylinositol 4-phosphate, phosphatidylinositol (4,5)-biphosphate, phosphatidylinositol (3,4,5)-biphosphate, phosphatidic acid, and phosphatidylserine. GSDMD also exhibits bactericidal activity.

Gasdermin-D (Gasdermin domain-containing protein 1) [Cleaved into: Gasdermin-D, N-terminal (GSDMD-NT) (hGSDMD-NTD); Gasdermin-D, C-terminal (GSDMD-CT) (hGSDMD-CTD); Gasdermin-D, p13 (Gasdermin-D, 13 kDa) (13 kDa GSDMD); Gasdermin-D, p40]GSDMD DFNA5L GSDMDC1 FKSG10

Human, Mouse, Rat

WB,IF/IHC

WB1:1000-1:2000； IF/IHC 1:100-1:1000

53kD(full),35kD(cleaved);

GSDMD DFNA5L GSDMDC1 FKSG10

P57764

Rabbit

Polyclonal

Rabbit IgG

GSDMD Antibody detects endogenous levels of total GSDMD protein, including precursor and the cleaved N-terminal fragment.

Inflammatory response #Innate immunity #defense response to bacterium

PBS, pH 7.4, 40% glycerol, and 0.01% sodium azide.

Store at -20 °C. Stable for 12 months from date of receipt.